DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Safe Pro Group ( $SPAI ) Deep Dive: Why Today’s U.S. Army Exercise Matters
Today’s update did not change the fact that Safe Pro is still a very early, very promotional, very high-risk small cap. What it did change is the quality of the operating narrative. Safe Pro is no longer talking only about future opportunity in defense AI. It is now stacking a visible sequence of milestones: a government subcontract, rapid delivery, Army exercises, commercial rollout of NODE-X, and another field validation event announced today.
Aurora Cannabis ( $ACB ) Is Building a Medical Export Engine, Not Waiting for U.S. Legalization
The real Aurora story in 2026 is not a vague bet on American reform. It is a much more specific and, arguably, much more investable thesis: a disciplined medical cannabis platform using Germany, Australia, EU-GMP infrastructure, and capacity expansion to build a higher-margin international business while many peers remain trapped in weaker market structures.
Amazon ($AMZN), Globalstar ($GSAT), and AST SpaceMobile ($ASTS): why Amazon’s Globalstar deal matters far beyond one takeover
Amazon’s move on Globalstar is not just another satellite headline. It is a deeper attempt to own spectrum, device-level connectivity, Apple continuity, and a bigger slice of the space economy at the same time. That has immediate implications for Globalstar, material strategic implications for Amazon, and a more complicated read-through for AST SpaceMobile.
Sidus Space ( $SIDU ): Lonestar StarVault Expansion, FY2025 Deep Dive & the LS-4 Test
Lonestar just expanded its StarVault relationship with Sidus, but the real question is not whether the story sounds exciting. The real question is whether Sidus can convert contracts, hosted payload wins and defense positioning into revenue before burn and dilution overwhelm the setup.
What Axsome ($AXSM), Rhythm ($RYTM), Crinetics ($CRNX), and Veracyte ($VCYT) Have in Common
Plenty of companies announce an earnings date. Very few deserve a dedicated article just because of that. What makes this group worth watching is that each company is walking into its next business update with a specific pressure point that matters more than the quarter itself.
Fastly (FSLY): verified April 2026 deep dive on the edge-security rerating thesis
Fastly is no longer the same simple “broken CDN turnaround” story it looked like a couple of years ago. The April 2026 setup is more nuanced. The business is showing real improvement in mix and operating profile, 2025 revenue accelerated to 15% growth, free cash flow turned positive, non-GAAP operating income turned positive for the full year, and management guided to another year of revenue growth plus positive non-GAAP operating income in 2026. That is the hard foundation the market was missing for a long time.
Draganfly ( $DPRO ) Deep Dive: balance sheet first, defense optionality second, execution proof still required
A full bilingual EN/IT report for WordPress Custom HTML on Draganfly’s current setup, product stack, defense traction, financial reality, dilution profile, scenario map, and the catalysts that matter after the company’s early-2026 funding reset.
Teva Pharmaceuticals: Pivot to Growth, Now Under Real Market Scrutiny
Teva entered 2026 with a more credible transformation story than it had just a few years ago. The company reported 2025 revenue of $17.3 billion, up 4% year over year, marking its third consecutive year of growth. That matters because Teva is still carrying the legacy of a global generics business, but the mix is gradually shifting toward innovative medicines, biosimilars, and pipeline assets that management believes can support more durable long-term growth.
Travere Therapeutics ( $TVTX ) after FILSPARI’s FDA approval in FSGS
Travere Therapeutics did not just clear another FDA box on April 13, 2026. It materially changed the shape of its equity story. FILSPARI, already commercial in IgA nephropathy, now has a second FDA-approved kidney disease indication: reduction of proteinuria in adults and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis, or FSGS, without nephrotic syndrome. That is a narrower label than the most aggressive bulls had once hoped for, but it is still a real commercial approval, not a consolation prize, and it makes FILSPARI the first and only FDA-approved medicine for FSGS.
HOTH Therapeutics (NASDAQ: $HOTH): today’s HT-VA GDNF update matters, but the balance sheet still controls the story
Hoth added another mechanistic layer to its HT-VA obesity / fatty-liver narrative today, with gene-level data showing reduced Srebf1 and increased Pparα in a VA / Emory CRADA model. That strengthens the scientific story, but it does not remove the core market question: can HOTH turn early preclinical promise and encouraging HT-001 oncology-supportive data into a financed, executable development path without crushing dilution?
One Stop Systems ( $OSS ) Deep Dive April 2026
From edge-AI pitch to real program conversion: what today’s autonomous-energy-node order says about OSS, how the business changed after the Bressner divestiture, and what still has to go right before this can be treated as a durable public-market winner.
Momentus ( $MNTS ) Deep Dive 2026 UPDATED APRIL15
Momentus is still one of the most binary small-cap space stories on the board, but after the last two weeks it is harder to dismiss the company as a pure concept trade. The central reason is not a promotional headline. It is sequence. For a company like MNTS, sequence is everything.
Ondas ( $ONDS) Deep Dive 2026 UPDATED APRIL 15
Static Finviz chart at the top. Referral applies only if a reader clicks through. NASDAQ: ONDS Defense · Counter-UAS · ISR · Robotics Updated April 13, 2026 Ondas (ONDS) Deep Dive April 2026 From a narrow drone narrative to a…
Allogene Therapeutics (ALLO) Deep Dive April 2026
Allogene Therapeutics has spent years trying to prove that allogeneic, off-the-shelf CAR-T can become something more than a clever scientific pitch. Today’s ALPHA3 interim futility analysis does not finish that argument, but it materially changes the tone of it.
Revolution Medicines ( $RVMD ) Deep Dive April 2026
Daraxonrasib just turned a long-building RAS story into a frontline market conversation. The key question is no longer whether Revolution Medicines has a serious pancreatic program. The question now is how large the platform can become, how quickly the company can convert today’s Phase 3 win into approvals, and how much upside still remains after a violent breakout.
Biotech Catalyst Day: IDEAYA ( $IDYA) and Spyre ( $SYRE) head into a parallel clinical readout window
Two biotech names, two very different clinical stories, one synchronized release window. IDEAYA and Spyre are both scheduled to report clinically meaningful updates on Monday, April 13, 2026 at 8:00 a.m. ET, creating an unusually clean side-by-side setup for traders watching biotech volatility, narrative rotation, and cross-flow behavior before the actual readouts hit.
AMC Entertainment ( $AMC) Deep Dive – April 2026
AMC is showing genuine operating improvement, but the common stock is still a highly leveraged instrument sitting underneath a very heavy capital structure.
Plug Power ( $PLUG) Deep Dive — April 2026
The tone around PLUG has improved because the company finally delivered concrete signs of stabilization: positive Q4 gross profit, lower cash burn, a clearer execution roadmap, a new CEO, a signed strategic asset sale, and a fresh commercial win in electrolyzers. The key question now is no longer just survival. It is whether improving liquidity can translate into sustainable industrial execution.
USA Rare Earth ( $USAR ): a strategic mine-to-magnet buildout, not a simple rare-earth headline trade
A long-form look at how USA Rare Earth is trying to build an integrated non-China rare earth chain across Texas, Oklahoma, the U.K. and France, why the story now matters far beyond mining, and where the real upside and real execution risk sit today.
Ocean Power Technologies ( $OPTT): Full Deep Dive on the Transition Story, the Capital Risk, and What Has to Happen Next
OPTT is no longer just the old “wave energy” micro-cap many traders remember. The company is trying to reposition itself as a maritime domain awareness and autonomous ocean systems story, with PowerBuoys, WAM-V platforms, Merrows software, defense-adjacent deployments, and a growing pipeline. The opportunity is obvious. The problem is obvious too: the revenue line is still tiny, the cash burn remains heavy, and the balance sheet still leans on dilution and convertible financing.